S&P 500   3,781.51 (-0.25%)
DOW   30,276.57 (-0.13%)
QQQ   281.24 (-0.32%)
AAPL   145.98 (-0.08%)
MSFT   248.58 (-0.12%)
META   138.22 (-1.47%)
GOOGL   101.03 (-0.60%)
AMZN   120.45 (-0.53%)
TSLA   238.57 (-4.36%)
NVDA   130.89 (-0.59%)
NIO   15.89 (-5.02%)
BABA   84.16 (+0.06%)
AMD   67.39 (-0.75%)
T   15.97 (-0.75%)
MU   54.52 (+1.04%)
CGC   3.01 (-4.14%)
F   12.44 (+0.65%)
GE   67.62 (+0.12%)
DIS   99.97 (-1.45%)
AMC   7.29 (-6.90%)
PYPL   93.56 (+0.83%)
PFE   44.23 (-0.52%)
NFLX   235.00 (-2.38%)
S&P 500   3,781.51 (-0.25%)
DOW   30,276.57 (-0.13%)
QQQ   281.24 (-0.32%)
AAPL   145.98 (-0.08%)
MSFT   248.58 (-0.12%)
META   138.22 (-1.47%)
GOOGL   101.03 (-0.60%)
AMZN   120.45 (-0.53%)
TSLA   238.57 (-4.36%)
NVDA   130.89 (-0.59%)
NIO   15.89 (-5.02%)
BABA   84.16 (+0.06%)
AMD   67.39 (-0.75%)
T   15.97 (-0.75%)
MU   54.52 (+1.04%)
CGC   3.01 (-4.14%)
F   12.44 (+0.65%)
GE   67.62 (+0.12%)
DIS   99.97 (-1.45%)
AMC   7.29 (-6.90%)
PYPL   93.56 (+0.83%)
PFE   44.23 (-0.52%)
NFLX   235.00 (-2.38%)
S&P 500   3,781.51 (-0.25%)
DOW   30,276.57 (-0.13%)
QQQ   281.24 (-0.32%)
AAPL   145.98 (-0.08%)
MSFT   248.58 (-0.12%)
META   138.22 (-1.47%)
GOOGL   101.03 (-0.60%)
AMZN   120.45 (-0.53%)
TSLA   238.57 (-4.36%)
NVDA   130.89 (-0.59%)
NIO   15.89 (-5.02%)
BABA   84.16 (+0.06%)
AMD   67.39 (-0.75%)
T   15.97 (-0.75%)
MU   54.52 (+1.04%)
CGC   3.01 (-4.14%)
F   12.44 (+0.65%)
GE   67.62 (+0.12%)
DIS   99.97 (-1.45%)
AMC   7.29 (-6.90%)
PYPL   93.56 (+0.83%)
PFE   44.23 (-0.52%)
NFLX   235.00 (-2.38%)
S&P 500   3,781.51 (-0.25%)
DOW   30,276.57 (-0.13%)
QQQ   281.24 (-0.32%)
AAPL   145.98 (-0.08%)
MSFT   248.58 (-0.12%)
META   138.22 (-1.47%)
GOOGL   101.03 (-0.60%)
AMZN   120.45 (-0.53%)
TSLA   238.57 (-4.36%)
NVDA   130.89 (-0.59%)
NIO   15.89 (-5.02%)
BABA   84.16 (+0.06%)
AMD   67.39 (-0.75%)
T   15.97 (-0.75%)
MU   54.52 (+1.04%)
CGC   3.01 (-4.14%)
F   12.44 (+0.65%)
GE   67.62 (+0.12%)
DIS   99.97 (-1.45%)
AMC   7.29 (-6.90%)
PYPL   93.56 (+0.83%)
PFE   44.23 (-0.52%)
NFLX   235.00 (-2.38%)
NYSE:AGE

AgeX Therapeutics - AGE Stock Forecast, Price & News

$0.56
+0.01 (+1.91%)
(As of 10/5/2022 01:17 PM ET)
Add
Compare
Today's Range
$0.55
$0.56
50-Day Range
$0.55
$0.73
52-Week Range
$0.52
$1.39
Volume
1,332 shs
Average Volume
18,850 shs
Market Capitalization
$21.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AGE stock logo

About AgeX Therapeutics (NYSE:AGE) Stock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGE Stock News Headlines

AgeX Therapeutics, Inc. (AGE)
AgeX Therapeutics GAAP EPS of -$0.07
AgeX Therapeutics, Inc. Common Stock (AGE)
AgeX Therapeutics, LyGenesis End Merger Talks
See More Headlines
Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGE Company Calendar

Last Earnings
8/12/2022
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
6
Year Founded
N/A

Profitability

Net Income
$-8,680,000.00
Net Margins
-13,877.94%
Pretax Margin
-14,032.36%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
($0.31) per share

Miscellaneous

Free Float
35,960,000
Market Cap
$21.25 million
Optionable
Not Optionable
Beta
1.44

Key Executives

  • Dr. Michael D. West Ph.D. (Age 69)
    Founder, Pres, CEO & Director
    Comp: $561.28k
  • Ms. Eun-Jae Park CPA (Age 50)
    Chief Financial Officer
    Comp: $279.32k
  • Dr. Nafees Naseer Malik M.D. (Age 44)
    Chief Operating Officer
    Comp: $282.27k
  • Dr. Ivan Labat
    Chief Information Officer
  • Ms. Judith Segall (Age 69)
    Sec.













AGE Stock - Frequently Asked Questions

How have AGE shares performed in 2022?

AgeX Therapeutics' stock was trading at $1.09 at the beginning of the year. Since then, AGE shares have decreased by 49.6% and is now trading at $0.5495.
View the best growth stocks for 2022 here
.

When is AgeX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AGE earnings forecast
.

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics, Inc. (NYSE:AGE) released its earnings results on Friday, August, 12th. The company reported ($0.07) earnings per share for the quarter. The firm earned $0.01 million during the quarter.

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), Ampio Pharmaceuticals (AMPE), AzurRx BioPharma (AZRX) and Digital Ally (DGLY).

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

How do I buy shares of AgeX Therapeutics?

Shares of AGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $0.55.

How much money does AgeX Therapeutics make?

AgeX Therapeutics (NYSE:AGE) has a market capitalization of $20.85 million and generates $140,000.00 in revenue each year.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The official website for the company is www.agexinc.com. The company can be reached via phone at (510) 671-8370 or via fax at 510-871-4154.

This page (NYSE:AGE) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.